In December 2023, Boston Scientific Corporation (NYSE: BSX) initiated the AVANT GUARD trial to evaluate the safety and ...

Boston Scientific (BSX) shares fell 5% following news that the company has paused a study for its FARAPULSE PFA system due to ...

The med-tech company with approximately 9,400 employees in Minnesota posted profit and sales that beat Wall Street’s ...

Boston Scientific is keeping the ball rolling in pulsed field ablation, posting 177% electrophysiology growth in the third ...

Boston Scientific reported third-quarter results that came in ahead of the consensus forecast, raising its 2024 guidance ...

Demand for the pulsed field ablation device drove the company’s electrophysiology sales up 177% in the third quarter compared ...

Despite a trial pause, Boston Scientific's impressive Q3 results and strategic expansions hint at a promising growth ...

Boston Scientific received FDA approval for its navigation-enabled Farawave Nav ablation catheter and clearance for new ...

William Plovanic, an analyst from Canaccord Genuity, maintained the Buy rating on Boston Scientific (BSX – Research Report). The ...

Analysis of Boston Scientific Corporation's Q3 results, future growth projections, and potential impact of regulatory ...

In this photo illustration, a Boston Scientific Corporation logo seen ... [+] displayed on a smartphone and pc screen in the ...

Wells Fargo raised the firm’s price target on Boston Scientific (BSX) to $98 from $87 and keeps an Overweight rating on the shares. The ...